KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

Background In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib (triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and trametinib (doublet) without reaching statistical significance. Mature results on PFS, duration of response (DOR), and overall survi...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Antoni Ribas, Inge Marie Svane, Paolo Antonio Ascierto, Victoria Atkinson, Razi Ghori, Anna Maria Di Giacomo, Georgina V Long, Henrik Schmidt, Jacob Schachter, Eduard Gasal, Paola Queirolo, Michal Lotem, Michele Del Vecchio, Pier Francesco Ferrucci, Rosalie Stephens, Mahmoud Abu-Amna, Scott J Diede, Elizabeth S Croydon
Format:	Artigo
Sprog:	Inglês
Udgivet:	BMJ Publishing Group 2020-10-01
Serier:	Journal for ImmunoTherapy of Cancer
Online adgang:	https://jitc.bmj.com/content/8/2/e001806.full
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!